O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma.

ABSTRACT: BACKGROUND:Treatment of glioblastoma (GB), the most common malignant primary brain tumor in adults, can include alkylating chemo-therapeutic agents. Two molecular biomarkers of treatment response are MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation and IDH (isocitrate dehydrogenase) mutations, which prevent repair of tumor cell DNA damage caused by alkylating chemotherapy. The status of MGMT promoter methylation and IDH mutation are associated with longer survival and a better response to chemotherapy. OBJECTIVE:Assess the prognostic value of MGMT methylation status and IDH mutation in adult Saudi glioblastoma patients. DESIGN:Retrospective, comparative survival analysis. SETTING:Tertiary care center. PATIENTS AND METHODS:The status of the MGMT promoter methylation and ID

SUBMITTER: Alassiri AH 

PROVIDER: S-EPMC6894451 | biostudies-literature | 2019 Nov-Dec

REPOSITORIES: biostudies-literature